How Long Can You Live With Heart Failure With Preserved EF?

Most people diagnosed with heart failure with preserved ejection fraction (HFpEF) live for several years after diagnosis, but the range is enormous. One large U.S. modeling study estimated about six years of remaining life expectancy from an average diagnosis age of 72, while a registry of nearly 40,000 hospitalized patients found a median survival of roughly two years. The gap between those numbers reflects a core truth about HFpEF: how long you live depends less on the diagnosis itself and more on your age, your other health conditions, and how your body responds to treatment. The science here is more nuanced than a single number can capture, and the factors that tilt the odds are worth understanding.

What the Survival Numbers Actually Show

Survival statistics for HFpEF vary widely depending on who was studied and how they were found. A population-based study that tracked patients over five years found that only about 43% of those with HFpEF were still alive at the five-year mark, compared with 72% in the age- and sex-matched general population without heart failure.¹ A large U.S. registry of patients hospitalized for heart failure between 2005 and 2009, encompassing nearly 40,000 people, reported an overall median survival of about two years and a five-year mortality rate around 76% for HFpEF patients.² Those numbers sound bleak, but they come from hospitalized populations, which are sicker on average than all people living with the condition.

A more recent U.S. analysis estimated that from a typical diagnosis age of 72, a person with HFpEF could expect about 6.1 years of remaining life.³ The difference between that figure and the grimmer registry data comes down to who is counted. Registry studies that enroll people during a hospital stay for acute heart failure are capturing patients at a crisis point. Studies that identify patients through community screening or outpatient records tend to find people earlier in their disease and produce more favorable numbers. Neither set of numbers is wrong; they describe different slices of the same population.

How HFpEF Survival Compares to Heart Failure With Reduced EF

For years, the assumption was that HFpEF was milder than heart failure with reduced ejection fraction (HFrEF) because the heart’s pumping strength looks normal on imaging. The survival data tell a more complicated story. In the large U.S. registry, after adjusting for risk factors, five-year mortality was nearly identical: about 75% for both HFpEF and HFrEF.² The population-based study found essentially the same thing, with five-year survival rates of 43% for HFpEF versus 46% for HFrEF.¹

Other studies do find a survival advantage for HFpEF. An international study across Singapore and New Zealand reported that after adjusting for age, sex, and clinical risk factors, HFpEF patients had about a 38% lower risk of death than those with HFrEF.⁴ A Polish cohort found a similar pattern, with five-year survival around 59% for HFpEF compared with 47% for HFrEF, and a 61% higher adjusted death risk in HFrEF patients.⁵ The takeaway is that HFpEF may carry a modestly better prognosis than HFrEF in some populations, but neither form of heart failure is benign, and the gap between them is far smaller than most people expect.

What People With HFpEF Actually Die From

One of the most striking features of HFpEF is that it kills differently than HFrEF. In HFrEF, most deaths are directly cardiac: the weakened heart fails or develops a fatal rhythm disturbance. In HFpEF, noncardiac causes account for a much larger share. A study examining cause of death across heart failure subtypes found that noncardiac causes accounted for 62% of deaths in HFpEF, compared with 35% in HFrEF.⁶ Cancer was twice as common as a cause of death in HFpEF versus HFrEF in that same analysis.

Among the cardiac deaths, sudden death accounts for roughly 25% to 30% in HFpEF trial populations, though the definition of “sudden death” is imprecise, and it is unclear how many of those represent true arrhythmic events versus other acute causes.⁷ Data from the PARAGON-HF trial, which enrolled nearly 5,000 patients, showed 60% of deaths were cardiovascular and 32% were noncardiovascular.⁸ This matters because it means the conditions you have alongside HFpEF, like diabetes, lung disease, or cancer, may pose as great a threat to your life as the heart failure itself.

How Age and Sex Shape the Outlook

Age is the single strongest predictor of survival in HFpEF. An analysis from the TOPCAT trial found that patients aged 85 or older had nearly seven times the risk of death compared with those 55 and younger.⁹ Yet the picture is not a simple “older equals worse.” Younger HFpEF patients, while living longer overall, were more likely to die suddenly when they did die, and they actually reported worse quality of life than their much older counterparts. Older patients, meanwhile, were more likely to die from noncardiovascular causes, reflecting the higher burden of other diseases that comes with advanced age.

Sex also plays a role. Women make up the majority of HFpEF patients, tend to be slightly older at diagnosis, and more often have obesity and hypertension. Men are more likely to have an underlying ischemic cause and atrial fibrillation. Despite these differences, women consistently show better survival. In the I-PRESERVE trial, women had a 36% lower risk of death than men over about four years of follow-up, and this advantage persisted even after adjusting for baseline differences.¹⁰ The survival benefit for women, however, was weaker when atrial fibrillation, kidney dysfunction, or advanced symptoms were present.¹¹

Why Comorbidities Matter More in HFpEF

HFpEF is sometimes called a disease of comorbidities. Patients tend to arrive at diagnosis carrying a load of other conditions: high blood pressure, diabetes, obesity, chronic kidney disease, lung disease, anemia, and more. The interaction between these conditions and heart failure is especially punishing. Research using national data found that each additional comorbidity raised the one-year adjusted risk of death by about 19% in HFpEF, compared with 10% per added comorbidity in HFrEF.¹² In other words, the same list of medical problems shortens life more steeply when paired with HFpEF than with HFrEF.

Certain conditions stand out. Chronic obstructive pulmonary disease (COPD) was associated with a particularly high mortality risk in HFpEF patients, more so than in HFrEF patients.¹³ This may be because COPD and HFpEF both cause breathlessness, leading to delayed diagnosis and compounding the physical limitations. Diabetes, hypertension, and kidney disease are also especially common and harmful in this population. Managing those conditions aggressively is not just good general medicine; it is one of the few reliable ways to improve how long and how well you live with HFpEF.

When Pulmonary Hypertension Enters the Picture

One of the more serious complications in HFpEF is pulmonary hypertension, where the blood pressure in the arteries leading to the lungs rises above normal. This happens because the stiff left side of the heart backs up blood flow into the lungs. When the lung vessels themselves begin to remodel and resist flow on their own, the condition progresses to a more severe form that carries worse outcomes.¹⁴ Elevated pulmonary vascular resistance, in particular, was associated with a roughly 54% higher risk of death in one large analysis.¹⁵

Imaging studies have confirmed that once pulmonary hypertension develops, the right side of the heart comes under strain. How well the right ventricle copes with that extra workload predicts survival. Cardiac MRI markers reflecting right ventricular function were independently associated with death in these patients.¹⁶ Unfortunately, treatments specifically targeting pulmonary hypertension in HFpEF remain limited, making early detection and management of the underlying heart failure all the more important.

Atrial Fibrillation as a Turning Point

Atrial fibrillation (AF) affects roughly two-thirds of HFpEF patients at some point during their illness and acts as a clear marker of worsening prognosis.¹⁷ In a community-based study, AF that developed after the heart failure diagnosis doubled the risk of death, even after accounting for other risk factors. AF that was present before or at the time of diagnosis also raised the risk, though less dramatically.

A large pooled analysis of clinical trials confirmed the pattern: among HFpEF patients, those with AF had about a 20% higher risk of the combined outcome of cardiovascular death or heart failure hospitalization compared to those in normal rhythm.¹⁸ The irregular rhythm reduces the heart’s filling efficiency, which is already impaired in HFpEF, and it promotes blood clots and stroke. Aggressive management of AF, through rate control, rhythm control, or anticoagulation, is a key part of the treatment plan.

What Treatments Can and Cannot Do

For decades, the medications that dramatically improved survival in HFrEF, including ACE inhibitors, beta-blockers, and angiotensin receptor blockers, were tried in HFpEF without clear success. The biology is different: these drugs target neurohormonal pathways that play a more prominent role when the heart is weakened than when it is stiff.¹⁹

The biggest recent advance is SGLT2 inhibitors, a class of drugs originally developed for diabetes. Multiple meta-analyses have shown that SGLT2 inhibitors reduce the combined risk of cardiovascular death or heart failure hospitalization by about 20% in HFpEF, and heart failure hospitalizations specifically by about 26%.²⁰ These benefits hold regardless of whether the patient has diabetes.²¹ The catch is that SGLT2 inhibitors have not been shown to reduce death on their own in HFpEF. Cardiovascular mortality and all-cause mortality were not significantly lowered in the pooled analyses.²⁰ They keep people out of the hospital and feeling better, but the survival benefit remains uncertain.

Spironolactone, a mineralocorticoid receptor antagonist, has shown mixed results overall in HFpEF but may benefit specific subgroups. A recent analysis found that patients with an enlarged left atrium and increased left ventricular mass got meaningful reductions in cardiovascular death and heart failure hospitalization from spironolactone, while the broader HFpEF population did not.²² This underscores a broader theme: HFpEF is probably not one disease but a collection of overlapping conditions, and treatments that fail in the overall group may work in the right subgroup.

Exercise as a Treatment

If there is one intervention that consistently improves life with HFpEF, it is structured exercise. A meta-analysis of randomized trials found that exercise training improved peak oxygen consumption by about 2 mL/kg/min, a clinically meaningful gain, and significantly improved quality-of-life scores.²³ A joint scientific statement from the American Heart Association and American College of Cardiology noted that exercise-based interventions have “consistently demonstrated large, significant, clinically meaningful improvements” in symptoms and exercise capacity, making exercise arguably the most reliably effective treatment for the syndrome.²⁴

What exercise has not clearly been shown to do is change heart function itself. A separate meta-analysis found that while six-minute walk distance and peak VO₂ both improved with training, measures of cardiac filling and ejection fraction did not shift.²⁵ The benefits seem to come from improvements in the muscles, blood vessels, and overall fitness rather than from fixing the heart’s stiffness. For a person with HFpEF, that distinction may feel academic: what matters is that you can walk farther, breathe easier, and feel better. Whether large-scale exercise programs can also extend life is not yet established, but the functional gains alone make a strong case.

The Obesity Paradox

Weight and HFpEF have a confusing relationship. Obesity is one of the strongest risk factors for developing HFpEF in the first place. Yet once you have the diagnosis, being moderately overweight or mildly obese appears to be associated with better survival than being at a normal weight. A meta-analysis of individual patient data found that HFpEF patients with a BMI of 25 to 35 had lower death rates than those with a BMI under 22.5.²⁶

This is not a free pass for excess weight, however. A more recent study found that where the fat sits matters as much as how much there is. Patients with a BMI of 40 or higher had a 64% higher risk of death compared with those in the mild obesity range. And when researchers used measures of abdominal fat distribution rather than BMI, higher values consistently predicted worse outcomes, with no paradoxical protection.²⁷ The paradox may partly reflect the limitations of BMI, which conflates muscle mass, subcutaneous fat, and visceral fat. Maintaining fitness and avoiding central obesity are likely more important than chasing a particular number on the scale.

Cognitive Decline and Its Prognostic Weight

A finding that often surprises patients and families is the connection between HFpEF and thinking problems. Analysis from the PARAGON-HF trial, which tested cognitive function using a standard screening tool, found that patients who scored lower at baseline had a stepwise increase in their risk of heart failure hospitalization, cardiovascular death, and death from any cause. Those with the lowest scores had about a 58% higher risk of the combined outcome compared to those with normal scores.²⁸

Even more telling, a decline in cognitive test scores during follow-up predicted worse outcomes going forward. A drop of three or more points was associated with a 53% higher risk of death from any cause and a 89% higher risk of cardiovascular death.²⁹ The relationship likely runs in both directions: heart failure reduces blood flow and contributes to brain changes, while cognitive impairment makes it harder to follow medication regimens, recognize worsening symptoms, and seek timely care. For families, this is a practical signal. If you notice memory or thinking problems in someone with HFpEF, it is worth flagging with their care team, both for its own sake and as a possible marker of disease progression.

Socioeconomic Factors and Access to Care

Your prognosis with HFpEF is shaped partly by circumstances that have nothing to do with your heart. Living alone was associated with a 77% higher risk of death in one study of patients with diastolic heart failure, and limitations in performing daily activities more than doubled the risk.³⁰ Having a professional occupation, a rough proxy for income and education, was linked to lower cardiovascular death in the same analysis.

Insurance type and race also influence outcomes. A large study of hospitalized HFpEF patients found that those with commercial insurance had about a 29% lower mortality risk than those on Medicaid. Black patients had higher readmission rates for heart failure and all causes, though their ten-year restricted mean survival was modestly higher than that of White patients in the same analysis.³¹ That last finding may reflect age differences between groups, as Black patients tend to be diagnosed younger. The overall message is that social supports, financial resources, and healthcare access can be as consequential for survival as the medications you take.

Palliative Care and Advanced Disease

HFpEF is a progressive condition. Even with optimal treatment, many patients eventually enter a phase where symptoms become difficult to manage, hospitalizations recur, and quality of life deteriorates. Palliative care, which focuses on symptom relief and quality of life rather than on curing the disease, has shown benefits in this context. A study of HFpEF patients in their last three years of life found that palliative care consultation was associated with reduced unwanted healthcare use and improved symptoms.³² Despite these benefits, palliative care remains underused in HFpEF, partly because the condition lacks the clear trajectory of advanced cancer and partly because many patients and clinicians associate palliative care only with dying. Raising the topic earlier, well before the final months, can help ensure that care remains aligned with what actually matters to the patient.

Hidden Causes Within HFpEF

One reason prognosis varies so widely is that HFpEF is an umbrella diagnosis. Some patients classified as HFpEF actually have a specific underlying condition masquerading as garden-variety heart failure. Cardiac amyloidosis, in which abnormal proteins deposit in the heart muscle and stiffen it, is a notable example. Patients with cardiac amyloidosis tolerate standard heart failure medications poorly and tend to have worse outcomes than those with other causes of HFpEF.³³ Diagnosing amyloidosis matters because targeted treatments now exist for certain forms. Blood biomarker panels that look beyond traditional markers are also being developed to identify which patients are at highest risk and might benefit from earlier or more targeted intervention.³⁴ As the ability to sort HFpEF into biologically distinct subgroups improves, the question of “how long can you live” will increasingly depend on which kind of HFpEF you have, not just the label itself.